Literature DB >> 27799976

Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus.

Shamsa Shariatpanahi1, Shahryar Pourfarzam1, Mohammadhosein Gheini2.   

Abstract

Macrophage Activating Syndrome (MAS) is a life-threatening disease seen in autoimmune diseases including lupus erythematosus, rheumatoid arthritis, Still's disease, polyarteritis nodosa. It is characterized by fever, pancytopenia, liver failure, coagulopathy, and neurologic symptoms and high serum ferritin. A 27 yr. old female patient was admitted in shahid Mostafa Khomeini Hospital (Tehran-Iran) in May 2011 because of lower extremities edema and ascites and fever from 1.5 month ago. In physical examinations she had generalized lymphadenopathy, splenomegaly and pleural effusion. In laboratory tests she had pancytopenia, positive ANA and Anti DNA (ds), hypocomplementemia, hypertriglyceridemia and high ferritin level. Gradually she had signs of RPGN and ARDS. The patient had no skin and musculoskeletal signs of SLE and no liver failure nor coagulopathy of MAS. Her lymph node biopsy was reported as Castleman syndrome. Unlike other studies, the patient showed MAS before treatment with cytotoxic for lupus nephritis.

Entities:  

Keywords:  Castleman syndrome; Macrophage activating syndrome; Systemic lupus erythematosus; hemophagocytic lymphohistiosytosis

Year:  2016        PMID: 27799976      PMCID: PMC5079460     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  30 in total

1.  Systemic lupus erythematosus and Castleman's disease.

Authors:  S Suwannaroj; S L Elkins; R W McMurray
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

2.  The incidence of macrophage activation syndrome in children with rheumatic disorders.

Authors:  M H Moradinejad; V Ziaee
Journal:  Minerva Pediatr       Date:  2011-12       Impact factor: 1.312

3.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

4.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine.

Authors:  A Ravelli; F De Benedetti; S Viola; A Martini
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

5.  Still's disease and the virus-associated haemophagocytic syndrome.

Authors:  J A Morris; A R Adamson; P J Holt; J Davson
Journal:  Ann Rheum Dis       Date:  1985-05       Impact factor: 19.103

6.  Systemic lupus erythematosus (SLE) lymphadenopathy presenting with histopathologic features of Castleman' disease: a clinicopathologic study of five cases.

Authors:  M Kojima; S Nakamura; H Itoh; K Yoshida; S Asano; N Yamane; S Komatsumoto; S Ban; T Joshita; T Suchi
Journal:  Pathol Res Pract       Date:  1997       Impact factor: 3.250

Review 7.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases.

Authors:  R Mouy; J L Stephan; P Pillet; E Haddad; P Hubert; A M Prieur
Journal:  J Pediatr       Date:  1996-11       Impact factor: 4.406

8.  High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome.

Authors:  D S Gill; A Spencer; R G Cobcroft
Journal:  Br J Haematol       Date:  1994-09       Impact factor: 6.998

9.  Systemic connective tissue disease complicated by Castleman's disease: report of a case and review of the literature.

Authors:  Ginevra De Marchi; Salvatore De Vita; Martina Fabris; Cathryn Ann Scott; Gianfranco Ferraccioli
Journal:  Haematologica       Date:  2004-04       Impact factor: 9.941

10.  Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis.

Authors:  Athimalaipet V Ramanan; Norman D Rosenblum; Brian M Feldman; Ronald M Laxer; Rayfel Schneider
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

View more
  3 in total

Review 1.  Systemic lupus erythematosus complicated with Castleman disease: a case-based review.

Authors:  Fatma Gül Demirkan; Sümeyra Doğan; Ayşe Kalyoncu Uçar; Hafize Emine Sönmez; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-08-14       Impact factor: 2.631

2.  Castleman disease and paraneoplastic pemphigus in a pregnant woman: A case report.

Authors:  Beibei Cui; Hui Lin
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

3.  A Case of Spondyloarthritis in Patient Affected by Unicentric Castleman's Disease Effectively Managed with Surgery Resection and Tocilizumab Treatment.

Authors:  M Filippini; S Cartella; O Bonzanini; E Morello; A Tincani
Journal:  Case Rep Rheumatol       Date:  2018-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.